Cessatech announces superior simulated pain efficacy in children favouring its lead candidate CT001 relative to its active comparators.

• The simulated pain reduction in NRS in children using CT001 was -87%, compared to -52%, -32% and +10% for sufentanil, ketamine and placebo respectively.
• Estimates for the opioid sparing effect of ketamine showed a need for more than double the sufentanil exposure to get the same overall effect seen with the treatment of CT001.
• The data supports the earlier reported data from the Dental Study 0205 showing the effectiveness of treatment with CT001. The full simulated data set will be presented at the PAGE conference in Rome 26-28 June.

On 3 June – Cessatech A/S (“Cessatech” or “the Company”) announces the final simulated efficacy data in children with CT001 from the abstract that will be presented at the Population Approach Group Europe (PAGE) conference in Rome Italy, during 26-28 June 2024.

The simulated pain reduction in Numeric Rating Scale (NRS) in children using CT001 was -87% (76%/92%) with a 95% CI for n=37. When using sufentanil alone the change in NRS was -52% (34%/65%) and with ketamine it was -32% (12%/47%), with a +10% (1%/20%) increase for placebo.

The pain relief estimated for CT001 would be difficult to obtain with sufentanil in children and would likely require more than double the sufentanil exposure, while increasing sufentanil or ketamine exposure could lead to side-effects like respiratory depression or hallucinogenic effects. Only 9% of children are expected to require a second dose of CT001.

[…]